|
|
|
|
In 1998, Yatai Group entered the pharmacy industry, and now makes great strides in research and development in biomedicine and modern traditional Chinese medicine. Yatai Pharmacy Industry has formed three-two-two configuration of industrial activities, that is three production bases: the base of biomedicine, the base of traditional Chinese medicine for anti-cancer and the base of traditional Chinese medicine for common use, two centers of new medicine research and development and medicine sale, two networks involving in retailing and wholesaling of medicine. Yatai Pharmacy Co., Ltd has independently developed Rg3, a new type of traditional Chinese medicine for anti-cancer. The company owns the patent for this product. Rg3 is the first national and international Grade One anti-cancer traditional Chinese medicine. It has been recognized as a national new product. The patented, ‘Shenyi?capsule has gone into production, and has gained the support from the national ‘Torch Program? Rg3 has been recognized as new high technology by the State. The new theory of micro-missile guided biomedicine for anti-cancer has been jointly researched and developed by Yatai Group and Military Supply University of the People’s Liberation Army, and its core technology has reached international advanced level. This resulted in experimental inhibition of tumors reaching 62%. Jilin Yatai Bio-Pharmaceuticals Co., Ltd. has passed National GMP Certification, and its main product ‘Purified Hydrophobia Vaccine?is in the lead in the terms of skilled production in the country. The market share is 25%, but the supply still falls short in the demand for purified hamster cell rabies vaccine. Jilin Yatai Bio-Pharmaceuticals Co., Ltd. also produces a wide range of peptide and genetic products in its biomedicine range.
|
|
Send mail to
webmaster@yatai.com with
questions or comments about this web site.
|
